Guidelines

Testicular Cancer

10. REFERENCES

1.Albers, P., et al. Guidelines on Testicular Cancer: 2015 Update. Eur Urol, 2015. 68: 1054.

https://www.sciencedirect.com/science/article/abs/pii/S0302283815007034

2.Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995.

https://pubmed.ncbi.nlm.nih.gov/18456631/

3.Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924.

https://pubmed.ncbi.nlm.nih.gov/18436948/

4.Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.

https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009

5.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.

https://pubmed.ncbi.nlm.nih.gov/18467413/

6.Park, J.S., et al. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore), 2018. 97: e12390.

https://pubmed.ncbi.nlm.nih.gov/30213007/

7.Nigam, M., et al. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol, 2014.

https://pubmed.ncbi.nlm.nih.gov/25030752/

8.Gurney, J.K., et al. International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries. Eur Urol, 2019. 76: 615.

https://pubmed.ncbi.nlm.nih.gov/31324498/

9.Oosterhuis, J.W., et al. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer, 2005. 5: 210.

https://pubmed.ncbi.nlm.nih.gov/15738984/

10.Looijenga, L.H.J., et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors. Am J Surg Pathol, 2020. 44: e66.

https://pubmed.ncbi.nlm.nih.gov/32205480/

11.Mostert, M.M., et al. Comparative genomic hybridization of germ cell tumors of the adult testis: confirmation of karyotypic findings and identification of a 12p-amplicon. Cancer Genet Cytogenet, 1996. 89: 146.

https://pubmed.ncbi.nlm.nih.gov/8697422/

12.Rosenberg, C., et al. Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas. Oncogene, 2000. 19: 5858.

https://pubmed.ncbi.nlm.nih.gov/11127816/

13.Oosterhuis, J.W., et al. Human germ cell tumours from a developmental perspective. Nat Rev Cancer, 2019. 19: 522.

https://pubmed.ncbi.nlm.nih.gov/31413324/

14.Jorgensen, N., et al. Testicular dysgenesis syndrome comprises some but not all cases of hypospadias and impaired spermatogenesis. Int J Androl, 2010. 33: 298.

https://pubmed.ncbi.nlm.nih.gov/20132348/

15.Lip, S.Z., et al. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child, 2013. 98: 20.

https://pubmed.ncbi.nlm.nih.gov/23193201/

16.Del Giudice, F., et al. Association between male infertility and male-specific malignancies: systematic review and meta-analysis of population-based retrospective cohort studies. Fertil Steril, 2020. 114: 984.

https://pubmed.ncbi.nlm.nih.gov/32709378/

17.Slowikowska-Hilczer, J., et al. Risk of gonadal neoplasia in patients with disorders/differences of sex development. Cancer Epidemiol, 2020. 69: 101800.

https://pubmed.ncbi.nlm.nih.gov/32905884/

18.Bosl, G.J., et al. Testicular germ-cell cancer. N Engl J Med, 1997. 337: 242.

https://pubmed.ncbi.nlm.nih.gov/9227931/

19.Greene, M.H., et al. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer, 2010. 17: R109.

https://pubmed.ncbi.nlm.nih.gov/20228134/

20.Lutke Holzik, M.F., et al. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol, 2004. 5: 363.

https://pubmed.ncbi.nlm.nih.gov/15172357/

21.Kharazmi, E., et al. Cancer Risk in Relatives of Testicular Cancer Patients by Histology Type and Age at Diagnosis: A Joint Study from Five Nordic Countries. Eur Urol, 2015. 68: 283.

https://pubmed.ncbi.nlm.nih.gov/25913387/

22.Schaapveld, M., et al. Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. Br J Cancer, 2012. 107: 1637.

https://pubmed.ncbi.nlm.nih.gov/23059747/

23.Peng, X., et al. The association risk of male subfertility and testicular cancer: a systematic review. PLoS One, 2009. 4: e5591.

https://pubmed.ncbi.nlm.nih.gov/19440348/

24.Seikkula, H., et al. Familial aggregation of testicular cancer among early-onset cancer survivors. A prospective observational cohort data from Finland. Cancer Epidemiol, 2020. 69: 101807.

https://pubmed.ncbi.nlm.nih.gov/33045472/

25.Pluta, J., et al. Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nat Commun, 2021. 12: 4487.

https://pubmed.ncbi.nlm.nih.gov/34301922/

26.Williamson, S.R., et al. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017. 70: 335.

https://pubmed.ncbi.nlm.nih.gov/27747907/

27.Brierley, J.E., et al., The TNM Classification of Malignant Tumours 8th edition. 2016.

https://www.uicc.org/resources/tnm-classification-malignant-tumours-8th-edition

28.Amin, M.B.E., et al. AJCC Cancer Staging Manual. 8th ed. AJCC Cancer Staging Manual. 2017.

https://link.springer.com/book/9783319406176

29.Klepp, O., et al. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol, 1990. 1: 281.

https://pubmed.ncbi.nlm.nih.gov/1702312/

30.Verhoeven, R.H., et al. Markedly increased incidence and improved survival of testicular cancer in the Netherlands. Acta Oncol, 2014. 53: 342.

https://pubmed.ncbi.nlm.nih.gov/23992111/

31.Gillessen, S., et al. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol, 2021. 39: 1563.

https://pubmed.ncbi.nlm.nih.gov/33822655/

32.Beyer, J., et al. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol, 2021. 39: 1553.

https://pubmed.ncbi.nlm.nih.gov/33729863/

33.Germa-Lluch, J.R., et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol, 2002. 42: 553.

https://pubmed.ncbi.nlm.nih.gov/12477650/

34.Moul, J. Timely diagnosis of testicular cancer. Urol Clin North Am, 2007. 34: 109.

https://pubmed.ncbi.nlm.nih.gov/17484916/

35.Mieritz, M.G., et al. Gynaecomastia in 786 adult men: clinical and biochemical findings. Eur
J Endocrinol, 2017. 176: 555.

https://pubmed.ncbi.nlm.nih.gov/28179453/

36.Shaw, J. Diagnosis and treatment of testicular cancer. Am Fam Phys, 2008. 77: 469.

https://pubmed.ncbi.nlm.nih.gov/18326165/

37.Angulo, J.C., et al. Clinicopathological study of regressed testicular tumors (apparent extragonadal germ cell neoplasms). J Urol, 2009. 182: 2303.

https://pubmed.ncbi.nlm.nih.gov/19762049/

38.Mancini, M., et al. High prevalence of testicular cancer in azoospermic men without spermatogenesis. Hum Reprod, 2007. 22: 1042.

https://pubmed.ncbi.nlm.nih.gov/17220165/

39.Isidori, A.M., et al. Differential diagnosis of nonpalpable testicular lesions: qualitative and quantitative contrast-enhanced US of benign and malignant testicular tumors. Radiology, 2014. 273: 606.

https://pubmed.ncbi.nlm.nih.gov/24968192/

40.Maizlin, Z.V., et al. Leydig cell tumors of the testis: gray scale and color Doppler sonographic appearance. J Ultrasound Med, 2004. 23: 959.

https://pubmed.ncbi.nlm.nih.gov/15292565/

41.Pedersen, M.R., et al. Elastography and diffusion-weighted MRI in patients with testicular microlithiasis, normal testicular tissue, and testicular cancer: an observational study. Acta Radiol, 2019. 60: 535.

https://pubmed.ncbi.nlm.nih.gov/29969051/

42.Rocher, L., et al. Characterization of Testicular Masses in Adults: Performance of Combined Quantitative Shear Wave Elastography and Conventional Ultrasound. Ultrasound Med Biol, 2019. 45: 720.

https://pubmed.ncbi.nlm.nih.gov/30600129/

43.Pierorazio, P.M., et al. Performance Characteristics of Clinical Staging Modalities for Early Stage Testicular Germ Cell Tumors: A Systematic Review. J Urol, 2020. 203: 894.

https://pubmed.ncbi.nlm.nih.gov/31609176/

44.Leibovitch, L., et al. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol, 1995. 154: 1759.

https://pubmed.ncbi.nlm.nih.gov/7563341/

45.Feldman, D.R., et al. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol, 2016. 34: 345.

https://pubmed.ncbi.nlm.nih.gov/26460295/

46.Cassidy, F.H., et al. MR imaging of scrotal tumors and pseudotumors. Radiographics, 2010. 30: 665.

https://pubmed.ncbi.nlm.nih.gov/20462987/

47.Kim, W., et al. US MR imaging correlation in pathologic conditions of the scrotum. Radiographics, 2007. 27: 1239.

https://pubmed.ncbi.nlm.nih.gov/17848688/

48.Manganaro, L., et al. A prospective study on contrast-enhanced magnetic resonance imaging of testicular lesions: distinctive features of Leydig cell tumours. Eur Radiol, 2015. 25: 3586.

https://pubmed.ncbi.nlm.nih.gov/25981218/

49.Tsili, A.C., et al. When to ask for an MRI of the scrotum. Andrology, 2021. 9: 1395.

https://pubmed.ncbi.nlm.nih.gov/33964115/

50.de Wit, M., et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol, 2008. 19: 1619.

https://pubmed.ncbi.nlm.nih.gov/18453520/

51.Sohaib, S.A., et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol, 2009. 64: 362.

https://pubmed.ncbi.nlm.nih.gov/19264179/

52.Huddart, R.A., et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol, 2007. 25: 3090.

https://pubmed.ncbi.nlm.nih.gov/17634488/

53.Oechsle, K., et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol, 2008. 26: 5930.

https://pubmed.ncbi.nlm.nih.gov/19018083/

54.Beyer, J., et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol, 2013. 24: 878.

https://pubmed.ncbi.nlm.nih.gov/23152360/

55.De Santis, M., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol, 2004. 22: 1034.

https://pubmed.ncbi.nlm.nih.gov/15020605/

56.Bachner, M., et al. 2-(1)(8)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol, 2012. 23: 59.

https://pubmed.ncbi.nlm.nih.gov/21460378/

57.Cathomas, R., et al. Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol, 2018. 36: JCO1800210.

https://pubmed.ncbi.nlm.nih.gov/30285559/

58.Gilligan, T.D., et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol, 2010. 28: 3388.

https://pubmed.ncbi.nlm.nih.gov/20530278/

59.Dieckmann, K.P., et al. Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment. Biomed Res Int, 2019. 2019: 5030349.

https://pubmed.ncbi.nlm.nih.gov/31275973/

60.Barlow, L.J., et al. Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol, 2010. 7: 610.

https://pubmed.ncbi.nlm.nih.gov/21068762/

61.Mead, G.M., et al. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol), 1997. 9: 207.

https://pubmed.ncbi.nlm.nih.gov/9315391/

62.Seidel, C., et al. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). Urol Oncol, 2019. 37: 809 e19.

https://pubmed.ncbi.nlm.nih.gov/31494007/

63.Nicholson, B.D., et al. The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: A diagnostic test accuracy systematic review. Cancer Epidemiol, 2019. 59: 15.

https://pubmed.ncbi.nlm.nih.gov/30658216/

64.Dieckmann, K.P., et al. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. Eur Urol, 2017. 71: 213.

https://pubmed.ncbi.nlm.nih.gov/27495845/

65.Dieckmann, K.P., et al. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol, 2019. 37: 1412.

https://pubmed.ncbi.nlm.nih.gov/30875280/

66.Nappi, L., et al. Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol, 2019. 37: 3090.

https://pubmed.ncbi.nlm.nih.gov/31553692/

67.Leao, R., et al. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. J Urol, 2018. 200: 126.

https://pubmed.ncbi.nlm.nih.gov/29474847/

68.Almstrup, K., et al. Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nat Rev Urol, 2020. 17: 201.

https://pubmed.ncbi.nlm.nih.gov/32157202/

69.Leão, R., et al. Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. Eur Urol, 2021. 80: 456.

https://pubmed.ncbi.nlm.nih.gov/34175151/

70.Lobo, J., et al. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur Urol Oncol, 2021. 4: 483.

https://pubmed.ncbi.nlm.nih.gov/33288479/

71.Belge, G., et al. Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin. J Cancer Res Clin Oncol, 2021. 147: 435.

https://pubmed.ncbi.nlm.nih.gov/33200255/

72.Patel, H.D., et al. Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: A systematic review and meta-analysis. Urol Oncol, 2020. 38: 344.

https://pubmed.ncbi.nlm.nih.gov/32192891/

73.Loy, V., et al. Incidence and distribution of carcinoma in situ in testes removed for germ cell tumour: possible inadequacy of random testicular biopsy in detecting the condition. Histopathology, 1990. 16: 198.

https://pubmed.ncbi.nlm.nih.gov/2323743/

74.Dieckmann, K.P., et al. Carcinoma in situ of the testis: review of biological and clinical features. Int
J Cancer, 1999. 83: 815.

https://pubmed.ncbi.nlm.nih.gov/10597201/

75.Nason, G.J., et al. Partial orchiectomy: The Princess Margaret cancer centre experience. Urol Oncol, 2020. 38: 605 e19.

https://pubmed.ncbi.nlm.nih.gov/32284257/

76.Dieckmann, K.P., et al. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol, 2007. 51: 175.

https://pubmed.ncbi.nlm.nih.gov/16814456/

77.Fankhauser, C.D., et al. The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis. Eur Urol Focus, 2020.

https://pubmed.ncbi.nlm.nih.gov/32684510/

78.Bieniek, J.M., et al. Prevalence and Management of Incidental Small Testicular Masses Discovered on Ultrasonographic Evaluation of Male Infertility. J Urol, 2018. 199: 481.

https://pubmed.ncbi.nlm.nih.gov/28789946/

79.Scandura, G., et al. Incidentally detected testicular lesions <10 mm in diameter: can orchidectomy be avoided? BJU Int, 2018. 121: 575.

https://pubmed.ncbi.nlm.nih.gov/29032579/

80.Matei, D.V., et al. Reliability of Frozen Section Examination in a Large Cohort of Testicular Masses: What Did We Learn? Clin Genitourin Cancer, 2017. 15: e689.

https://pubmed.ncbi.nlm.nih.gov/28216275/

81.Elert, A., et al. Accuracy of frozen section examination of testicular tumors of uncertain origin. Eur Urol, 2002. 41: 290.

https://pubmed.ncbi.nlm.nih.gov/12180230/

82.Favilla, V., et al. Oncological and functional outcomes of testis sparing surgery in small testicular mass: a systematic review. Minerva Urol Nephrol, 2021. 73: 431.

https://pubmed.ncbi.nlm.nih.gov/33949185/

83.Skoogh, J., et al. Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. Int J Androl, 2011. 34: 183.

https://pubmed.ncbi.nlm.nih.gov/20550599/

84.Robinson, R., et al. Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy. BJU Int, 2016. 117: 249.

https://pubmed.ncbi.nlm.nih.gov/25168859/

85.Dieckmann, K.P., et al. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol, 1996. 14: 3126.

https://pubmed.ncbi.nlm.nih.gov/8955658/

86.Ruf, C.G., et al. Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular intra-epithelial neoplasia. Andrology, 2015. 3: 92.

https://pubmed.ncbi.nlm.nih.gov/25146646/

87.Andreassen, K.E., et al. Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007). Int J Cancer, 2011. 129: 2867.

https://pubmed.ncbi.nlm.nih.gov/21626506/

88.Harland, S.J., et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol, 1998. 160: 1353.

https://pubmed.ncbi.nlm.nih.gov/9751353/

89.Tabernero, J., et al. Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol, 2004. 171: 164.

https://pubmed.ncbi.nlm.nih.gov/14665868/

90.Albers, P., et al. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. Urology, 1999. 54: 714.

https://pubmed.ncbi.nlm.nih.gov/10510934/

91.Heidenreich, A., et al. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? Semin Urol Oncol, 2002. 20: 234.

https://pubmed.ncbi.nlm.nih.gov/12489055/

92.Giwercman, A., et al. Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. J Urol, 1989. 142: 998.

https://pubmed.ncbi.nlm.nih.gov/2571738/

93.Souchon, R., et al. Contralateral testicular cancer in spite of TIN-negative double biopsies and interval cisplatin chemotherapy. Strahlenther Onkol, 2006. 182: 289.

https://pubmed.ncbi.nlm.nih.gov/16673063/

94.Moch, H.H., et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. 2016, Lyon.

https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016

95.Verrill, C., et al. Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am
J Surg Pathol, 2017. 41: e22.

https://pubmed.ncbi.nlm.nih.gov/28368923/

96.Verrill, C., et al. Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am
J Surg Pathol, 2018. 42: e33.

https://pubmed.ncbi.nlm.nih.gov/29579010/

97.Berney, D.M., et al. Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. Histopathology, 2019. 74: 171.

https://pubmed.ncbi.nlm.nih.gov/30565308/

98.Kuczyk, M.A., et al. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis. Cancer, 1996. 78: 1958.

https://pubmed.ncbi.nlm.nih.gov/8909317/

99.Force, U.S.P.S.T. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med, 2011. 154: 483.

https://pubmed.ncbi.nlm.nih.gov/21464350/

100.Ilic, D., et al. Screening for testicular cancer. Cochrane Database Syst Rev, 2011: CD007853.

https://pubmed.ncbi.nlm.nih.gov/21328302/

101.Thornton, C.P. Best Practice in Teaching Male Adolescents and Young Men to Perform Testicular Self-Examinations: A Review. J Pediatr Health Care, 2016. 30: 518.

https://pubmed.ncbi.nlm.nih.gov/26778347/

102.Bandak, M., et al. Preorchiectomy Leydig Cell Dysfunction in Patients With Testicular Cancer. Clin Genitourin Cancer, 2017. 15: e37.

https://pubmed.ncbi.nlm.nih.gov/27524512/

103.Rives, N., et al. The semen quality of 1158 men with testicular cancer at the time of cryopreservation: results of the French National CECOS Network. J Androl, 2012. 33: 1394.

https://pubmed.ncbi.nlm.nih.gov/22837112/

104.Petersen, P.M., et al. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol, 1999. 161: 822.

https://pubmed.ncbi.nlm.nih.gov/10022693/

105.Brydoy, M., et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol, 2010. 58: 134.

https://pubmed.ncbi.nlm.nih.gov/20395037/

106.Brydoy, M., et al. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br J Cancer, 2012. 107: 1833.

https://pubmed.ncbi.nlm.nih.gov/23169336/

107.Petersen, P.M., et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol, 2002. 20: 1537.

https://pubmed.ncbi.nlm.nih.gov/11896102/

108.Lampe, H., et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol, 1997.
15: 239.

https://pubmed.ncbi.nlm.nih.gov/8996148/

109.Weibring, K., et al. Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment. Ann Oncol, 2019. 30: 604.

https://pubmed.ncbi.nlm.nih.gov/30798330/

110.Gilbert, K., et al. Fertility preservation for men with testicular cancer: Is sperm cryopreservation cost effective in the era of assisted reproductive technology? Urol Oncol, 2018. 36: 92 e1.

https://pubmed.ncbi.nlm.nih.gov/29169844/

111.Jacobsen, K.D., et al. Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. Eur Urol, 2002. 42: 229.

https://pubmed.ncbi.nlm.nih.gov/12234507/

112.Nieschlag E, B.H., Pharmacology and clinical use of testosterone, In: Testosterone-Action, Deficiency, Substitution., B.H.M. Nieschlag E., Editor. 1999, Springer Verlag Berlin-Heidelberg-New York.

113.Arnon, J., et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update, 2001. 7: 394.

https://pubmed.ncbi.nlm.nih.gov/11476352/

114.Salonia, A., et al., EAU Guidelines on Sexual and Reproductive Health. 2022, The European Association of Urology: Arnhem, The Netherlands.

https://uroweb.org/guideline/sexual-and-reproductive-health/

115.Warde, P., et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol, 2002. 20: 4448.

https://pubmed.ncbi.nlm.nih.gov/12431967/

116.Aparicio, J., et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol, 2005. 23: 8717.

https://pubmed.ncbi.nlm.nih.gov/16260698/

117.Chung, P., et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med, 2015. 4: 155.

https://pubmed.ncbi.nlm.nih.gov/25236854/

118.Mortensen, M.S., et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol, 2014. 66: 1172.

https://pubmed.ncbi.nlm.nih.gov/25064686/

119.Aparicio, J., et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol, 2014. 25: 2173.

https://pubmed.ncbi.nlm.nih.gov/25210015/

120.Tandstad, T., et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol, 2016. 27: 1299.

https://pubmed.ncbi.nlm.nih.gov/27052649/

121.Boormans, J.L., et al. Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. Eur Urol, 2017.

https://pubmed.ncbi.nlm.nih.gov/29100813/

122.Zengerling, F., et al. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. Urol Oncol, 2017.

https://pubmed.ncbi.nlm.nih.gov/28712790/

123.Albers, P., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol, 2003. 21: 1505.

https://pubmed.ncbi.nlm.nih.gov/12697874/

124.Blok, J.M., et al. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis. BJU Int, 2020. 125: 355.

https://pubmed.ncbi.nlm.nih.gov/31797520/

125.Lobo, J., et al. Interobserver Agreement in Vascular Invasion Scoring and the Added Value of Immunohistochemistry for Vascular Markers to Predict Disease Relapse in Stage I Testicular Nonseminomas. Am J Surg Pathol, 2019. 43: 1711.

https://pubmed.ncbi.nlm.nih.gov/31490238/

126.Hoffmann, R., et al. Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005. Int J Public Health, 2014. 59: 341.

https://pubmed.ncbi.nlm.nih.gov/23989709/

127.Zengerling, F., et al. German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice. Oncol Rep, 2014. 31: 2477.

https://pubmed.ncbi.nlm.nih.gov/24788853/

128.Jones, A., et al. Is surveillance for stage 1 germ cell tumours of the testis appropriate outside a specialist centre? BJU Int, 1999. 84: 79.

https://pubmed.ncbi.nlm.nih.gov/10444129/

129.Collette, L., et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst, 1999. 91: 839.

https://pubmed.ncbi.nlm.nih.gov/10340903/

130.Schrader, M., et al. Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer? Eur Urol, 2010. 57: 867.

https://pubmed.ncbi.nlm.nih.gov/19931248/

131.Dieckmann, K.P., et al. Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Study Group. Ann Oncol, 2013. 24: 1332.

https://pubmed.ncbi.nlm.nih.gov/23293116/

132.Classen, J., et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer, 2003. 88: 828.

https://pubmed.ncbi.nlm.nih.gov/12644817/

133.Stephenson, A., et al. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.
J Urol, 2019. 202: 272.

https://pubmed.ncbi.nlm.nih.gov/31059667/

134.Hoei-Hansen, C.E., et al. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol, 2005. 16: 863.

https://pubmed.ncbi.nlm.nih.gov/15821122/

135.Cohn-Cedermark, G., et al. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Andrology, 2015. 3: 102.

https://pubmed.ncbi.nlm.nih.gov/25270123/

136.Kollmannsberger, C., et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol, 2015. 33: 51.

https://pubmed.ncbi.nlm.nih.gov/25135991/

137.Groll, R.J., et al. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol, 2007. 64: 182.

https://pubmed.ncbi.nlm.nih.gov/17644403/

138.Aparicio, J., et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol, 2003. 14: 867.

https://pubmed.ncbi.nlm.nih.gov/12796024/

139.Nayan, M., et al. Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. Eur Urol, 2017. 71: 120.

https://pubmed.ncbi.nlm.nih.gov/27527805/

140.Tandstad, T., et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol, 2011. 29: 719.

https://pubmed.ncbi.nlm.nih.gov/21205748/

141.Chung, P., et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol), 2010. 22: 6.

https://pubmed.ncbi.nlm.nih.gov/19775876/

142.Huang, M.M., et al. Cost-effectiveness Analysis of Non-risk-adapted Active Surveillance for Postorchiectomy Management of Clinical Stage I Seminoma. Eur Urol Focus, 2020.

https://pubmed.ncbi.nlm.nih.gov/32646809/

143.Oliver, R.T., et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet, 2005. 366: 293.

https://pubmed.ncbi.nlm.nih.gov/16039331/

144.Oliver, R.T., et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol, 2011. 29: 957.

https://pubmed.ncbi.nlm.nih.gov/21282539/

145.Mead, G.M., et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst, 2011. 103: 241.

https://pubmed.ncbi.nlm.nih.gov/21212385/

146.Fischer, S., et al. Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. J Clin Oncol, 2017. 35: 194.

https://pubmed.ncbi.nlm.nih.gov/27893332/

147.Fossa, S.D., et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group.
J Clin Oncol, 1999. 17: 1146.

https://pubmed.ncbi.nlm.nih.gov/10561173/

148.Jones, W.G., et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol, 2005. 23: 1200.

https://pubmed.ncbi.nlm.nih.gov/15718317/

149.Melchior, D., et al. Long term results and morbidity of paraaortic compared with paraaortic and iliac adjuvant radiation in clinical stage I seminoma. Anticancer Res, 2001. 21: 2989.

https://pubmed.ncbi.nlm.nih.gov/11712799/

150.Bieri, S., et al. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol, 1999. 50: 349.

https://pubmed.ncbi.nlm.nih.gov/10392822/

151.van den Belt-Dusebout, A.W., et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol, 2007. 25: 4370.

https://pubmed.ncbi.nlm.nih.gov/17906202/

152.Horwich, A., et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer, 2014. 110: 256.

https://pubmed.ncbi.nlm.nih.gov/24263066/

153.Patel, H.D., et al. Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urol Oncol, 2017. 35: 606 e1.

https://pubmed.ncbi.nlm.nih.gov/28712791/

154.Aparicio, J., et al. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. Clin Transl Oncol, 2021. 23: 58.

https://pubmed.ncbi.nlm.nih.gov/32462393/

155.Chakiryan, N.H., et al. Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review. J Urol, 2021. 205: 1569.

https://pubmed.ncbi.nlm.nih.gov/33617328/

156.Hamilton, R.J., et al. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. J Clin Oncol, 2019. 37: 1919.

https://pubmed.ncbi.nlm.nih.gov/30802156/

157.Klepp, O., et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. J Clin Oncol, 1990. 8: 509.

https://pubmed.ncbi.nlm.nih.gov/1689773/

158.Kollmannsberger, C., et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol, 2010. 21: 1296.

https://pubmed.ncbi.nlm.nih.gov/19875756/

159.Nichols, C.R., et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol, 2013. 31: 3490.

https://pubmed.ncbi.nlm.nih.gov/24002502/

160.Donohue, J.P., et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol, 1993. 149: 237.

https://pubmed.ncbi.nlm.nih.gov/8381190/

161.Nicolai, N., et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol, 2010. 58: 912.

https://pubmed.ncbi.nlm.nih.gov/20817343/

162.Nicolai, N., et al. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. J Urol, 2018. 199: 741.

https://pubmed.ncbi.nlm.nih.gov/28964782/

163.Heidenreich, A., et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol, 2003. 169: 1710.

https://pubmed.ncbi.nlm.nih.gov/12686815/

164.Al-Ahmadie, H.A., et al. Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy. Urology, 2013. 82: 1341.

https://pubmed.ncbi.nlm.nih.gov/24094656/

165.Albers, P., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol, 2008. 26: 2966.

https://pubmed.ncbi.nlm.nih.gov/18458040/

166.Pearce, S.M., et al. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol, 2017. 71: 476.

https://pubmed.ncbi.nlm.nih.gov/27234998/

167.Calaway, A.C., et al. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol, 2019. 76: 607.

https://pubmed.ncbi.nlm.nih.gov/31174891/

168.Rodrigues, G.J., et al. Robot-assisted retroperitoneal lymphadenectomy: The state of art. Asian
J Urol, 2021. 8: 27.

https://pubmed.ncbi.nlm.nih.gov/33569270/

169.Bhanvadia, R., et al. Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. World J Urol, 2021. 39: 1977.

https://pubmed.ncbi.nlm.nih.gov/32797261/

170.Schermerhorn, S.M.V., et al. Learning Curve for Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection. J Endourol, 2021. 35: 1483.

https://pubmed.ncbi.nlm.nih.gov/33559522/

171.Supron, A.D., et al. Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors: a single-surgeon experience. J Robot Surg, 2021. 15: 309.

https://pubmed.ncbi.nlm.nih.gov/32572754/

172.Taylor, J., et al. Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort. Eur Urol Focus, 2020.

https://pubmed.ncbi.nlm.nih.gov/32682794/

173.Hiester, A., et al. Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. J Urol, 2020. 204: 1242.

https://pubmed.ncbi.nlm.nih.gov/32717162/

174.Foster, R.S., et al. Clinical stage I nonseminoma: surgery versus surveillance. Semin Oncol, 1998. 25: 145.

https://pubmed.ncbi.nlm.nih.gov/9562447/

175.Cullen, M.H., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol, 1996. 14: 1106.

https://pubmed.ncbi.nlm.nih.gov/8648364/

176.Pont, J., et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol, 1996. 14: 441.

https://pubmed.ncbi.nlm.nih.gov/8636755/

177.Chevreau, C., et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol, 2004. 46: 209.

https://pubmed.ncbi.nlm.nih.gov/15245815/

178.Bohlen, D., et al. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol, 2001. 165: 441.

https://pubmed.ncbi.nlm.nih.gov/11176393/

179.Tandstad, T., et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol, 2009. 27: 2122.

https://pubmed.ncbi.nlm.nih.gov/19307506/

180.Tandstad, T., et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol, 2014. 25: 2167.

https://pubmed.ncbi.nlm.nih.gov/25114021/

181.Flechtner, H.H., et al. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. Eur Urol, 2016. 69: 518.

https://pubmed.ncbi.nlm.nih.gov/26620368/

182.Huddart, R.A., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol, 2003. 21: 1513.

https://pubmed.ncbi.nlm.nih.gov/12697875/

183.Westermann, D.H., et al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J Urol, 2008. 179: 163.

https://pubmed.ncbi.nlm.nih.gov/18001800/

184.Fischer, S., et al. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. J Clin Oncol, 2020. 38: 1322.

https://pubmed.ncbi.nlm.nih.gov/31877087/

185.Giannatempo, P., et al. Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. J Urol, 2016. 196: 95.

https://pubmed.ncbi.nlm.nih.gov/26748165/

186.Hajiran, A., et al. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Ann Surg Oncol, 2021. 28: 3648.

https://pubmed.ncbi.nlm.nih.gov/33689081/

187.Harari, S.E., et al. Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens. Urol Oncol, 2017. 35: 605.e9.

https://pubmed.ncbi.nlm.nih.gov/28647396/

188.Krege, S., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol, 2008. 53: 478.

https://pubmed.ncbi.nlm.nih.gov/18191324/

189.Lorch, A., et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol, 2010. 28: 4906.

https://pubmed.ncbi.nlm.nih.gov/20956623/

190.Aparicio, J., et al. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. J Urol, 2019. 202: 742.

https://pubmed.ncbi.nlm.nih.gov/31163007/

191.Classen, J., et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol, 2003. 21: 1101.

https://pubmed.ncbi.nlm.nih.gov/12637477/

192.Chung, P.W., et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol, 2004. 45: 754.

https://pubmed.ncbi.nlm.nih.gov/15149748/

193.Horwich, A., et al. Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann Oncol, 2013. 24: 2104.

https://pubmed.ncbi.nlm.nih.gov/23592702/

194.Hallemeier, C.L., et al. Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience. Urol Oncol, 2013. 31: 1832.

https://pubmed.ncbi.nlm.nih.gov/22537538/

195.Culine, S., et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol, 2007. 18: 917.

https://pubmed.ncbi.nlm.nih.gov/17351252/

196.Giannatempo, P., et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol, 2015. 26: 657.

https://pubmed.ncbi.nlm.nih.gov/25214543/

197.Krege, S., et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol, 2006. 17: 276.

https://pubmed.ncbi.nlm.nih.gov/16254023/

198.Horwich, A., et al. A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br J Cancer, 2000. 83: 1623.

https://pubmed.ncbi.nlm.nih.gov/11104556/

199.Alifrangis, C., et al. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. Eur J Cancer, 2020.

https://pubmed.ncbi.nlm.nih.gov/33041185/

200.Hu, B., et al. Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive Seminoma. Clin Genitourin Cancer, 2015. 13: e265.

https://pubmed.ncbi.nlm.nih.gov/25682512/

201.Tabakin, A.L., et al. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clin Genitourin Cancer, 2020. 18: e194.

https://pubmed.ncbi.nlm.nih.gov/31818649/

202.Baniel, J., et al. Late relapse of testicular cancer. J Clin Oncol, 1995. 13: 1170.

https://pubmed.ncbi.nlm.nih.gov/7537800/

203.Stephenson, A.J., et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
J Clin Oncol, 2007. 25: 5597.

https://pubmed.ncbi.nlm.nih.gov/18065732/

204.Douglawi, A., et al. Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant Chemotherapy. J Urol, 2020. 204: 96.

https://pubmed.ncbi.nlm.nih.gov/32003612/

205.McHugh, D.J., et al. Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. J Clin Oncol, 2020. 38: 1332.

https://pubmed.ncbi.nlm.nih.gov/32109195/

206.Bokemeyer, C., et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer, 2004. 91: 683.

https://pubmed.ncbi.nlm.nih.gov/15266338/

207.Fizazi, K., et al. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. Eur Urol, 2014. 65: 381.

https://pubmed.ncbi.nlm.nih.gov/24094847/

208.de Wit, R., et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol, 1997. 15: 1837.

https://pubmed.ncbi.nlm.nih.gov/9164193/

209.de Wit, R., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol, 2001. 19: 1629.

https://pubmed.ncbi.nlm.nih.gov/11250991/

210.Fossa, S.D., et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol, 2003. 21: 1107.

https://pubmed.ncbi.nlm.nih.gov/12637478/

211.Grimison, P.S., et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst, 2010. 102: 1253.

https://pubmed.ncbi.nlm.nih.gov/20631341/

212.Cary, K.C., et al. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors. J Urol, 2015. 193: 507.

https://pubmed.ncbi.nlm.nih.gov/25254937/

213.Fossa, S.D., et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol, 1998. 16: 716.

https://pubmed.ncbi.nlm.nih.gov/9469362/

214.de Wit, R., et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer, 1998. 78: 828.

https://pubmed.ncbi.nlm.nih.gov/9743309/

215.Nichols, C.R., et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol, 1998. 16: 1287.

https://pubmed.ncbi.nlm.nih.gov/9552027/

216.Daugaard, G., et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol, 2011. 22: 1054.

https://pubmed.ncbi.nlm.nih.gov/21059637/

217.Motzer, R.J., et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol, 2007. 25: 247.

https://pubmed.ncbi.nlm.nih.gov/17235042/

218.Fizazi, K., et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol, 2004. 22: 3868.

https://pubmed.ncbi.nlm.nih.gov/15302906/

219.Fizazi, K., et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol, 2014.
15: 1442.

https://pubmed.ncbi.nlm.nih.gov/25456363/

220.Bokemeyer, C., et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol, 2002. 20: 1864.

https://pubmed.ncbi.nlm.nih.gov/11919246/

221.Kollmannsberger, C., et al. Identification of prognostic subgroups among patients with metastatic ‘IGCCCG poor-prognosis’ germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol, 2000. 11: 1115.

https://pubmed.ncbi.nlm.nih.gov/11061604/

222.Bokemeyer, C., et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol, 1999. 17: 3450.

https://pubmed.ncbi.nlm.nih.gov/10550141/

223.Massard, C., et al. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol, 2010. 21: 1585.

https://pubmed.ncbi.nlm.nih.gov/20181575/

224.Gillessen, S., et al. Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience. Ann Oncol, 2010.
21: 1589.

https://pubmed.ncbi.nlm.nih.gov/20164149/

225.Woldu, S.L., et al. Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urol Oncol, 2018. 36: 14.e7.

https://pubmed.ncbi.nlm.nih.gov/28935185/

226.Piketty, A.C., et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer, 2005. 93: 909.

https://pubmed.ncbi.nlm.nih.gov/16205699/

227.Lauritsen, J., et al. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. J Clin Oncol, 2019. 38: 584.

https://pubmed.ncbi.nlm.nih.gov/31821065/

228.Fankhauser, C.D., et al. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. Eur Urol Focus, 2021. 7: 1130.

https://pubmed.ncbi.nlm.nih.gov/33032968/

229.Khorana, A.A., et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med, 2019. 380: 720.

https://pubmed.ncbi.nlm.nih.gov/30786186/

230.Carrier, M., et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl
J Med, 2019. 380: 711.

https://pubmed.ncbi.nlm.nih.gov/30511879/

231.Agnelli, G., et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med, 2012. 366: 601.

https://pubmed.ncbi.nlm.nih.gov/22335737/

232.Agnelli, G., et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol, 2009. 10: 943.

https://pubmed.ncbi.nlm.nih.gov/19726226/

233.Key, N.S., et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 2019: JCO.19.01461.

https://pubmed.ncbi.nlm.nih.gov/31381464/

234.Gizzi, M., et al. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer, 2016. 69: 151.

https://pubmed.ncbi.nlm.nih.gov/27821318/

235.Fankhauser, C.D., et al. Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. Eur Urol, 2019.

https://pubmed.ncbi.nlm.nih.gov/31718823/

236.Young, A.M., et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
J Clin Oncol, 2018. 36: 2017.

https://pubmed.ncbi.nlm.nih.gov/29746227/

237.Klok, F.A., et al. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev, 2014. 28: 221.

https://pubmed.ncbi.nlm.nih.gov/25168205/

238.Fankhauser, C.D., et al. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. Eur Urol, 2021. 80: 4.

https://pubmed.ncbi.nlm.nih.gov/33722419/

239.Haugnes, H.S., et al. Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000–2014: A Population-based Cohort Study. Eur Urol Open Sci, 2021. 32: 19.

https://pubmed.ncbi.nlm.nih.gov/34667955/

240.Gerl, A., et al. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer, 1993. 29A: 961.

https://pubmed.ncbi.nlm.nih.gov/7684597/

241.Murphy, B.A., et al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer, 1994.
73: 2520.

https://pubmed.ncbi.nlm.nih.gov/7513603/

242.Andre, F., et al. The growing teratoma syndrome: results of therapy and long-term follow-up of
33 patients. Eur J Cancer, 2000. 36: 1389.

https://pubmed.ncbi.nlm.nih.gov/10899652/

243.de Wit, R., et al. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer, 1998. 78: 1350.

https://pubmed.ncbi.nlm.nih.gov/9823978/

244.Zon, R.T., et al. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol, 1998. 16: 1294.

https://pubmed.ncbi.nlm.nih.gov/9552028/

245.Fossa, S.D., et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer, 1999. 80: 1392.

https://pubmed.ncbi.nlm.nih.gov/10424741/

246.Hofmockel, G., et al. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int, 1996. 57: 38.

https://pubmed.ncbi.nlm.nih.gov/8840489/

247.Kamat, M.R., et al. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J Surg Oncol, 1992. 51: 65.

https://pubmed.ncbi.nlm.nih.gov/1381455/

248.Loehrer, P.J., Sr., et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol, 1987. 5: 1212.

https://pubmed.ncbi.nlm.nih.gov/2442317/

249.Motzer, R., et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol, 1987. 5: 1064.

https://pubmed.ncbi.nlm.nih.gov/3598610/

250.Herr, H.W., et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol, 1997. 157: 860.

https://pubmed.ncbi.nlm.nih.gov/9072586/

251.Mosharafa, A.A., et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol, 2003. 169: 2126.

https://pubmed.ncbi.nlm.nih.gov/12771733/

252.Puc, H.S., et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol, 1996. 14: 454.

https://pubmed.ncbi.nlm.nih.gov/8636757/

253.Miki, T., et al. Post-chemotherapy nerve-sparing retroperitoneal lymph node dissection for advanced germ cell tumor. Int J Urol, 2009. 16: 379.

https://pubmed.ncbi.nlm.nih.gov/19191930/

254.Carver, B.S., et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol, 2007. 25: 5603.

https://pubmed.ncbi.nlm.nih.gov/17998544/

255.Nason, G.J., et al. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. Eur Urol Oncol, 2021. 4: 289.

https://pubmed.ncbi.nlm.nih.gov/32907779/

256.Ehrlich, Y., et al. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol, 2010. 28: 531.

https://pubmed.ncbi.nlm.nih.gov/20026808/

257.Hartmann, J.T., et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur
J Cancer, 1997. 33: 843.

https://pubmed.ncbi.nlm.nih.gov/9291803/

258.Hendry, W.F., et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer, 2002. 94: 1668.

https://pubmed.ncbi.nlm.nih.gov/11920527/

259.Sheinfeld, J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol, 2002. 20: 262.

https://pubmed.ncbi.nlm.nih.gov/12489059/

260.Steyerberg, E.W., et al. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Int J Cancer, 1999. 83: 856.

https://pubmed.ncbi.nlm.nih.gov/10597211/

261.Carver, B.S., et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol, 2007. 25: 1033.

https://pubmed.ncbi.nlm.nih.gov/17261854/

262.Oldenburg, J., et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol, 2003. 21: 3310.

https://pubmed.ncbi.nlm.nih.gov/12947067/

263.Rick, O., et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol, 2004. 22: 3713.

https://pubmed.ncbi.nlm.nih.gov/15365067/

264.Large, M.C., et al. Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int, 2009. 104: 1369.

https://pubmed.ncbi.nlm.nih.gov/19840015/

265.Heidenreich, A., et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol, 2009. 55: 217.

https://pubmed.ncbi.nlm.nih.gov/18926622/

266.Gerdtsson, A., et al. Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. Eur Urol Oncol, 2021.

https://pubmed.ncbi.nlm.nih.gov/33750683/

267.Beck, S.D., et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer, 2007. 110: 1235.

https://pubmed.ncbi.nlm.nih.gov/17665498/

268.Fizazi, K., et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol, 2008. 19: 259.

https://pubmed.ncbi.nlm.nih.gov/18042838/

269.Busch, J., et al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis. BMC Urol, 2012. 12: 15.

https://pubmed.ncbi.nlm.nih.gov/22651395/

270.Arai, Y., et al. Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes. Int Urol Nephrol, 2012. 44: 1389.

https://pubmed.ncbi.nlm.nih.gov/22648291/

271.Nicolai, N., et al. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. J Endourol, 2016. 30: 1112.

https://pubmed.ncbi.nlm.nih.gov/27533924/

272.Stepanian, S., et al. Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique. Eur Urol, 2016. 70: 661.

https://pubmed.ncbi.nlm.nih.gov/27068395/

273.Steyerberg, E.W., et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol, 1997. 158: 474.

https://pubmed.ncbi.nlm.nih.gov/9224327/

274.Besse, B., et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg, 2009. 137: 448.

https://pubmed.ncbi.nlm.nih.gov/19185168/

275.Schirren, J., et al. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. Thorac Cardiovasc Surg, 2012. 60: 405.

https://pubmed.ncbi.nlm.nih.gov/22383152/

276.Ehrlich, Y., et al. Vena caval reconstruction during postchemotherapy retroperitoneal lymph node dissection for metastatic germ cell tumor. Urology, 2009. 73: 442 e17.

https://pubmed.ncbi.nlm.nih.gov/18436290/

277.Heidenreich, A., et al. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol, 2017. 28: 362.

https://pubmed.ncbi.nlm.nih.gov/27831507/

278.Winter, C., et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol, 2012. 61: 403.

https://pubmed.ncbi.nlm.nih.gov/22078334/

279.Wells, H., et al. Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK - a national study. BJU Int, 2017. 119: 91.

https://pubmed.ncbi.nlm.nih.gov/27353395/

280.Capitanio, U., et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology, 2009. 74: 373.

https://pubmed.ncbi.nlm.nih.gov/19501893/

281.Flechon, A., et al. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int, 2010. 106: 779.

https://pubmed.ncbi.nlm.nih.gov/20089110/

282.Eggener, S.E., et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer, 2007. 109: 528.

https://pubmed.ncbi.nlm.nih.gov/17177200/

283.Oechsle, K., et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol, 2011. 60: 850.

https://pubmed.ncbi.nlm.nih.gov/21704446/

284.Nicolai, N., et al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int, 2009. 104: 340.

https://pubmed.ncbi.nlm.nih.gov/19239440/

285.Beck, S.D., et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol, 2005. 23: 6149.

https://pubmed.ncbi.nlm.nih.gov/16135481/

286.Fizazi, K., et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol, 2001. 19: 2647.

https://pubmed.ncbi.nlm.nih.gov/11352956/

287.Stenning, S.P., et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer, 1998. 83: 1409.

https://pubmed.ncbi.nlm.nih.gov/9762943/

288.Miller, K.D., et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol, 1997. 15: 1427.

https://pubmed.ncbi.nlm.nih.gov/9193335/

289.Fizazi, K., et al. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Ann Oncol, 2014. 25: 987.

https://pubmed.ncbi.nlm.nih.gov/24595454/

290.Mead, G.M., et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer, 2005. 93: 178.

https://pubmed.ncbi.nlm.nih.gov/15999102/

291.Pico, J.L., et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol, 2005. 16: 1152.

https://pubmed.ncbi.nlm.nih.gov/15928070/

292.Lorch, A., et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol, 2012. 30: 800.

https://pubmed.ncbi.nlm.nih.gov/22291076/

293.Oechsle, K., et al. Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor. Oncology, 2010. 78: 47.

https://pubmed.ncbi.nlm.nih.gov/20215785/

294.Agarwala, A.K., et al. Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma. Am J Clin Oncol, 2011. 34: 286.

https://pubmed.ncbi.nlm.nih.gov/20523207/

295.Berger, L.A., et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol, 2014. 140: 1211.

https://pubmed.ncbi.nlm.nih.gov/24696231/

296.Massard, C., et al. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol, 2013. 24: 322.

https://pubmed.ncbi.nlm.nih.gov/23104726/

297.Necchi, A., et al. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant, 2016. 51: 384.

https://pubmed.ncbi.nlm.nih.gov/26642334/

298.Bin Riaz, I., et al. Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. Bone Marrow Transplant, 2018. 53: 1242.

https://pubmed.ncbi.nlm.nih.gov/29703969/

299.Necchi, A., et al. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. Clin Genitourin Cancer, 2014. 12: 63.

https://pubmed.ncbi.nlm.nih.gov/24161525/

300.Mulherin, B.P., et al. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. Am J Clin Oncol, 2015.
38: 373.

https://pubmed.ncbi.nlm.nih.gov/26214082/

301.Lorch, A., et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol, 2007. 25: 2778.

https://pubmed.ncbi.nlm.nih.gov/17602082/

302.Oldenburg, J., et al. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol, 2006. 24: 5503.

https://pubmed.ncbi.nlm.nih.gov/17158535/

303.Oldenburg, J., et al. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer, 2006. 94: 820.

https://pubmed.ncbi.nlm.nih.gov/16508636/

304.George, D.W., et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis.
J Clin Oncol, 2003. 21: 113.

https://pubmed.ncbi.nlm.nih.gov/12506179/

305.Lee, A.H., et al. The value of central histopathological review of testicular tumours before treatment. BJU Int, 1999. 84: 75.

https://pubmed.ncbi.nlm.nih.gov/10444128/

306.Lipphardt, M.E., et al. Late relapse of testicular cancer. World J Urol, 2004. 22: 47.

https://pubmed.ncbi.nlm.nih.gov/15064970/

307.Fossa, S.D., et al. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer, 1999. 85: 988.

https://pubmed.ncbi.nlm.nih.gov/10091779/

308.Bokemeyer, C., et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol, 1997. 15: 1449.

https://pubmed.ncbi.nlm.nih.gov/9193339/

309.Hartmann J.T., et al. Multidiciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin. Proc Ann Soc Clin Oncol, 2003. 22: Abstract 1607. [No abstract available].

310.Honecker, F., et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol, 2018. 29: 1658.

https://pubmed.ncbi.nlm.nih.gov/30113631/

311.Hale, G.R., et al. Lymph node imaging in testicular cancer. Transl Androl Urol, 2018. 7: 864.

https://pubmed.ncbi.nlm.nih.gov/30456189/

312.Thomas, K.L., et al. The role of diagnostic imaging in the primary testicular cancer: initial staging, response assessment and surveillance. Transl Androl Urol, 2020. 9: S3.

https://pubmed.ncbi.nlm.nih.gov/32055480/

313.Laukka, M., et al. Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial. Acta Oncol, 2020. 59: 660.

https://pubmed.ncbi.nlm.nih.gov/32048533/

314.Loughrey, G.J., et al. The value of specialist oncological radiology review of cross-sectional imaging. Clin Radiol, 1999. 54: 149.

https://pubmed.ncbi.nlm.nih.gov/10201861/

315.Larsen, S.K.A., et al. Ten years of experience with MRI follow-up of testicular cancer stage I: a retrospective study and an MRI protocol with DWI. Acta Oncol, 2020. 59: 1374.

https://pubmed.ncbi.nlm.nih.gov/32684054/

316.Mortensen, M.S., et al. Late Relapses in Stage I Testicular Cancer Patients on Surveillance. Eur Urol, 2016. 70: 365.

https://pubmed.ncbi.nlm.nih.gov/26996661/

317.Travis, L.B., et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst, 2010. 102: 1114.

https://pubmed.ncbi.nlm.nih.gov/20585105/

318.Oldenburg, J., et al. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol, 2015. 26: 833.

https://pubmed.ncbi.nlm.nih.gov/25378299/

319.Hiester, A., et al. Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort. Eur
J Cancer, 2021. 155: 64.

https://pubmed.ncbi.nlm.nih.gov/34371444/

320.Agrawal, V., et al. Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. JNCI Cancer Spectr, 2020. 4: pkz079.

https://pubmed.ncbi.nlm.nih.gov/32190815/

321.Kerns, S.L., et al. Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. JNCI Cancer Spectr, 2020. 4: pkaa022.

https://pubmed.ncbi.nlm.nih.gov/32704617/

322.Haugnes, H.S., et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol, 2012. 30: 3752.

https://pubmed.ncbi.nlm.nih.gov/23008318/

323.Hellesnes, R., et al. Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study. J Clin Oncol, 2021. 39: 308.

https://pubmed.ncbi.nlm.nih.gov/33356420/

324.Blok, J.M., et al. Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. J Clin Oncol, 2021. 39: 319.

https://pubmed.ncbi.nlm.nih.gov/33119475/

325.Bright, C.J., et al. Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study. Lancet Oncol, 2019. 20: 531.

https://pubmed.ncbi.nlm.nih.gov/30797674/

326.Hauptmann, M., et al. Increased stomach cancer risk following radiotherapy for testicular cancer. Br J Cancer, 2015. 112: 44.

https://pubmed.ncbi.nlm.nih.gov/25349972/

327.Fung, C., et al. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol, 2013. 31: 3807.

https://pubmed.ncbi.nlm.nih.gov/24043737/

328.Groot, H.J., et al. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. J Clin Oncol, 2018. 36: 2504.

https://pubmed.ncbi.nlm.nih.gov/29989856/

329.Zhang, L., et al. Second cancers and causes of death in patients with testicular cancer in Sweden. PLoS One, 2019. 14: e0214410.

https://pubmed.ncbi.nlm.nih.gov/30921367/

330.Necchi, A., et al. Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 2018. 53: 722.

https://pubmed.ncbi.nlm.nih.gov/29367713/

331.Milano, M.T., et al. Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 241398042195900 Survivors. JNCI Cancer Spectr, 2020. 4: pkaa017.

https://pubmed.ncbi.nlm.nih.gov/32455335/

332.Howard, R., et al. Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients. Ann Epidemiol, 2008. 18: 416.

https://pubmed.ncbi.nlm.nih.gov/18433667/

333.Kollmannsberger, C., et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol, 1998. 16: 3386.

https://pubmed.ncbi.nlm.nih.gov/9779717/

334.Nichols, C.R., et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst, 1993. 85: 36.

https://pubmed.ncbi.nlm.nih.gov/7677934/

335.Fossa, S.D., et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst, 2007. 99: 533.

https://pubmed.ncbi.nlm.nih.gov/17405998/

336.O’Sullivan, J.M., et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol, 2003. 14: 91.

https://pubmed.ncbi.nlm.nih.gov/12488299/

337.Haugnes, H.S., et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol, 2009. 27: 2779.

https://pubmed.ncbi.nlm.nih.gov/19414680/

338.Necchi, A., et al. Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. Clin Genitourin Cancer, 2017. 15: 213.

https://pubmed.ncbi.nlm.nih.gov/27692810/

339.Lauritsen, J., et al. Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin. J Clin Oncol, 2016. 34: 1492.

https://pubmed.ncbi.nlm.nih.gov/26903578/

340.Calaway, A.C., et al. Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors. J Clin Oncol, 2018. 36: 2950.

https://pubmed.ncbi.nlm.nih.gov/30156983/

341.Kwan, E.M., et al. Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. Clin Genitourin Cancer, 2017.

https://pubmed.ncbi.nlm.nih.gov/28943331/

342.Fossa, S.D., et al. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer, 2004. 90: 607.

https://pubmed.ncbi.nlm.nih.gov/14760372/

343.Kerns, S.L., et al. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. J Clin Oncol, 2018. 36: 1505.

https://pubmed.ncbi.nlm.nih.gov/29617189/

344.van den Belt-Dusebout, A.W., et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol, 2006. 24: 467.

https://pubmed.ncbi.nlm.nih.gov/16421423/

345.Feldman, D.R., et al. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. Clin Genitourin Cancer, 2018. 16: e761.

https://pubmed.ncbi.nlm.nih.gov/29534941/

346.Haugnes, H.S., et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol, 2007. 18: 241.

https://pubmed.ncbi.nlm.nih.gov/17060482/

347.Alberti, K.G., et al. The metabolic syndrome--a new worldwide definition. Lancet, 2005. 366: 1059.

https://pubmed.ncbi.nlm.nih.gov/16182882/

348.Bogefors, C., et al. Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome. Andrology, 2017. 5: 711.

https://pubmed.ncbi.nlm.nih.gov/28544654/

349.Sprauten, M., et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol, 2012. 30: 300.

https://pubmed.ncbi.nlm.nih.gov/22184390/

350.Bjerring, A.W., et al. The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up. Eur Heart J Cardiovasc Imaging, 2021. 22: 443.

https://pubmed.ncbi.nlm.nih.gov/33152065/

351.Stelwagen, J., et al. Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy. Br J Cancer, 2020. 123: 1599.

https://pubmed.ncbi.nlm.nih.gov/32921790/

352.Adams, S.C., et al. Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial. Cancer, 2017. 123: 4057.

https://pubmed.ncbi.nlm.nih.gov/28708930/

353.Thorsen, et al. Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer. J Clin Oncol, 2017. 35: 4551.

https://pubmed.ncbi.nlm.nih.gov/32525564/

354.Teutsch, C., et al. Raynaud’s phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep, 1977. 61: 925.

https://pubmed.ncbi.nlm.nih.gov/70274/

355.Adoue, D., et al. Bleomycin and Raynaud’s phenomenon. Ann Intern Med, 1984. 100: 770.

https://pubmed.ncbi.nlm.nih.gov/6201095/

356.Vogelzang, N.J., et al. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med, 1981. 95: 288.

https://pubmed.ncbi.nlm.nih.gov/6168223/

357.Brydoy, M., et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst, 2009. 101: 1682.

https://pubmed.ncbi.nlm.nih.gov/19940282/

358.Hjelle, L.V., et al. Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors. Acta Oncol, 2018. 57: 1392.

https://pubmed.ncbi.nlm.nih.gov/29775128/

359.Skalleberg, J., et al. Speech perception 30 years after cisplatin-based chemotherapy in adults: limited clinical relevance of long-term ototoxicity? Acta Oncol, 2021. 60: 426.

https://pubmed.ncbi.nlm.nih.gov/33617403/

360.Skalleberg, J., et al. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up. Laryngoscope, 2020. 130: E515.

https://pubmed.ncbi.nlm.nih.gov/32065408/

361.Oldenburg, J., et al. Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics, 2008. 9: 1521.

https://pubmed.ncbi.nlm.nih.gov/18855538/

362.Oldenburg, J., et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol, 2007. 25: 708.

https://pubmed.ncbi.nlm.nih.gov/17228018/

363.Trendowski, M.R., et al. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res, 2020. 26: 6550.

https://pubmed.ncbi.nlm.nih.gov/32998964/

364.Amidi, A., et al. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav, 2017. 11: 769.

https://pubmed.ncbi.nlm.nih.gov/27240852/

365.Perry, D.J., et al. Enhanced bleomycin toxicity during acute renal failure. Cancer Treat Rep, 1982. 66: 592.

https://pubmed.ncbi.nlm.nih.gov/6174233/

366.Bennett, W.M., et al. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep, 1980. 64: 921.

https://pubmed.ncbi.nlm.nih.gov/6160913/

367.Ichioka, D., et al. Possible risk of overestimation of renal function using cystatin C-based eGFR in testicular cancer survivors treated with cisplatin-based chemotherapy. Clin Exp Nephrol, 2018.
22: 727.

https://pubmed.ncbi.nlm.nih.gov/28948387/

368.Garcia, S.L., et al. Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer Patients. JNCI Cancer Spectr, 2020. 4: pkaa032.

https://pubmed.ncbi.nlm.nih.gov/32617516/

369.Vidal, A.D., et al. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy. Ann Oncol, 2015. 26: 374.

https://pubmed.ncbi.nlm.nih.gov/25392157/

370.Bandak, M., et al. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin. Eur Urol Focus, 2016.

https://pubmed.ncbi.nlm.nih.gov/28753832/

371.Skøtt, J.W., et al. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction. Clin Genitourin Cancer, 2019. 17: e65.

https://pubmed.ncbi.nlm.nih.gov/30293923/

372.Wiechno, P.J., et al. Dynamics of hormonal disorders following unilateral orchiectomy for a testicular tumor. Med Oncol, 2017. 34: 84.

https://pubmed.ncbi.nlm.nih.gov/28389909/

373.Bandak, M., et al. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors. Eur J Cancer, 2017. 84: 9.

https://pubmed.ncbi.nlm.nih.gov/28772110/

374.Walsh, J.S., et al. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLoS Med, 2019. 16: e1002960.

https://pubmed.ncbi.nlm.nih.gov/31714912/

375.Bandak, M., et al. A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention). BMC Cancer, 2017. 17: 461.

https://pubmed.ncbi.nlm.nih.gov/28673265/

376.Orre, I.J., et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer.
J Psychosom Res, 2008. 64: 363.

https://pubmed.ncbi.nlm.nih.gov/18374735/

377.Abu Zaid, M., et al. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. J Natl Compr Canc Netw, 2019. 17: 459.

https://pubmed.ncbi.nlm.nih.gov/31085753/

378.Sprauten, M., et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol, 2014. 32: 571.

https://pubmed.ncbi.nlm.nih.gov/24419125/

379.Smith, A.B., et al. A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. Psychooncology, 2018. 27: 1129.

https://pubmed.ncbi.nlm.nih.gov/29171109/

380.Vehling, S., et al. Anxiety and depression in long-term testicular germ cell tumor survivors. Gen Hosp Psychiatry, 2016. 38: 21.

https://pubmed.ncbi.nlm.nih.gov/26439320/

381.Bandak, M., et al. Sexual Function in a Nationwide Cohort of 2,260 Survivors of Testicular Cancer after 17 Years of Followup. J Urol, 2018. 200: 794.

https://pubmed.ncbi.nlm.nih.gov/29730199/

382.Dahl, A.A., et al. Aspects of posttraumatic stress disorder in long-term testicular cancer survivors: cross-sectional and longitudinal findings. J Cancer Surviv, 2016. 10: 842.

https://pubmed.ncbi.nlm.nih.gov/26920871/

383.Kreiberg, M., et al. Psychological stress in long-term testicular cancer survivors: a Danish nationwide cohort study. J Cancer Surviv, 2020. 14: 72.

https://pubmed.ncbi.nlm.nih.gov/31748852/

384.Raphael, M.J., et al. Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. J Clin Oncol, 2021. 39: 779.

https://pubmed.ncbi.nlm.nih.gov/33507821/

385.Bandak, M., et al. Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular Cancer. Eur Urol Focus, 2020. 6: 711.

https://pubmed.ncbi.nlm.nih.gov/30482585/

386.Rosenberg, C., et al. Chromosomal constitution of human spermatocytic seminomas: Comparative genomic hybridization supported by conventional and interphase cytogenetics. Genes, Chromosomes and Cancer, 1998. 23: 286.

https://pubmed.ncbi.nlm.nih.gov/9824200/

387.Moch, H., et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2016. 70: 93.

https://pubmed.ncbi.nlm.nih.gov/26935559/

388.Grogg, J.B., et al. A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis. J Cancer Res Clin Oncol, 2019. 145: 3037.

https://pubmed.ncbi.nlm.nih.gov/31646373/

389.Idrees, M.T., et al. The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017. 70: 513.

https://pubmed.ncbi.nlm.nih.gov/27801954/

390.Ruf, C.G., et al. Leydig-cell tumour of the testis: retrospective analysis of clinical and therapeutic features in 204 cases. World J Urol, 2020. 38: 2857.

https://pubmed.ncbi.nlm.nih.gov/31960106/

391.Fankhauser, C.D., et al. Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. J Urol, 2020. 203: 949.

https://pubmed.ncbi.nlm.nih.gov/31845841/

392.Grogg, J., et al. Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. Oncologist, 2020. 25: 585.

https://pubmed.ncbi.nlm.nih.gov/32043680/

393.Grogg, J.B., et al. Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data. J Cancer Res Clin Oncol, 2020.
146: 2829.

https://pubmed.ncbi.nlm.nih.gov/32719989/

394.Zhang, M., et al. Testicular fibrothecoma: a morphologic and immunohistochemical study of 16 cases. Am J Surg Pathol, 2013. 37: 1208.

https://pubmed.ncbi.nlm.nih.gov/23715159/

395.Bhambhvani, H.P., et al. Primary malignancies of the epididymis: clinical characteristics and prognostic factors. Can J Urol, 2021. 28: 10522.

https://pubmed.ncbi.nlm.nih.gov/33625342/

396.Chowdhry, V.K., et al. Testicular, Spermatic Cord, and Scrotal Soft Tissue Sarcomas: Treatment Outcomes and Patterns of Failure. Sarcoma, 2021. 2021: 8824301.

https://pubmed.ncbi.nlm.nih.gov/33746565/

397.Radaelli, S., et al. Prognostic factors and outcome of spermatic cord sarcoma. Ann Surg Oncol, 2014. 21: 3557.

https://pubmed.ncbi.nlm.nih.gov/24802908/

398.Bharti, J.N., et al. Cytomorphological spectrum of epididymal nodules: An institution’s experience. Cytojournal, 2017. 14: 26.

https://pubmed.ncbi.nlm.nih.gov/29259652/

399.Tsili, A.C., et al. MRI of the scrotum: Recommendations of the ESUR Scrotal and Penile Imaging Working Group. Eur Radiol, 2018. 28: 31.

https://pubmed.ncbi.nlm.nih.gov/28698942/

400.Grogg, J.B., et al. Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. J Cancer Res Clin Oncol, 2021. 147: 2671.

https://pubmed.ncbi.nlm.nih.gov/33559739/